A British doctor warned that weight loss injections may cause a significant increase in the numbers of patients with osteoporosis, which may lead to the bankruptcy of the UK National Health Services Authority.
Millions of people around the world use weight loss injection, such as Mondarjo, Agawi and Azomic, which studies have shown to help people lose up to 20% of their weight.
A study published earlier this year found that 40% of this lost weight is a vital muscle and great mass, and it is concerned that this loss in the bone mass may lead to osteoporosis, a condition in which the bones weaken and become more fragile and prone to breakage.
The weight -loss expert, Dr. Paul Mason, said – in a recent interview with “GB News” that the British Daily Mail wrote – that the increase in these injuries may cause tremendous financial pressure on the National Health Services Authority. He added: “We do not want to bankrupt the health system because of this tsunami from the osteoporosis that approaches us.”
In response to increased anxiety, Mason called for a degree of organization to address the costs that he described as the catastrophic that these injuries may cause to the health system in the future.
He went further, and he said: “I think these medications will eventually be withdrawn from the market.”
Prevention is better than treatment
Hip fractures are usually a major cause of death and disability among the elderly, but there are fears that they may now affect the increasing number of young people who receive injections.
When the new research appeared, the Royal Association of Osteoporosis expressed its concerns about the effects of osteoporosis, and Julia Thompson, a specialized nurse at the association, told the Sunday Express newspaper: “This is an emerging research field, and people should be warned that using these drugs increases the risk of bone and muscles, as well as fat.”
She added: “The health of the bones and muscles is essential to prevent the risk of falling and fractures that may lead to premature death or negatively affect people’s ability to live independently.”
She stressed the need to prescribe the injection appropriately after consulting a doctor, because some people are more likely to this condition, for example women are more likely to develop osteoporosis, especially after menopause, as low estrogen levels lead to accelerating bone loss.
“Any drug that reduces muscle mass and bone density is a bad idea for people with fragility and exposed to fractures due to osteoporosis. The evidence is clear, these drugs carry great dangers, and the more the patient’s eating of it, the greater the dangers,” said Professor Karl Hingan, director of the UK University of Oxford Medical Center in Oxford.
He added that the focus should be on obesity, instead of “describing medicines for large segments of the population to be a quick solution to obesity.”